Eli Lilly (LLY) brushed off concerns about the impact of CVS Health's (CVS) decision to drop coverage of Lilly's Zepbound weight-loss drug from some of its health plans while retaining rival Novo Nordisk's (NVO) Wegovy.
"We're not surprised that this kind of thing was announced," Lilly Chief Executive David Ricks said on an earnings conference call Thursday, according to a FactSet transcript. "We're not interested at all in one-of-one deals of reducing access and choice for doctors and patients."
CVS did not immediately reply to MT Newswires' request for comment.
Lilly shares were up 2.4% in recent premarket activity Friday after closing nearly 12% lower Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。